The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

Anti-drug antibodies were produced at similar levels to Humira, but with no impact on safety and pharmacokinetics, Moses added. Ablynx noted that the placebo effect was highest in a group of ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today ...

House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review ...

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...